社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
junior_daddy
IP属地:未知
+关注
帖子 · 215
帖子 · 215
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
junior_daddy
junior_daddy
·
2021-11-16
Pls like
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars
看
1,364
回复
1
点赞
3
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-10
Pls like
非常抱歉,此主贴已删除
看
1,900
回复
1
点赞
5
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-09
Pls like
非常抱歉,此主贴已删除
看
1,871
回复
2
点赞
3
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Pls like
Regeneron shares rose 2.2% in premarket trading
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading
看
1,495
回复
5
点赞
10
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Pls like
Regeneron shares rose 2.2% in premarket trading
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading
看
1,300
回复
1
点赞
9
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Tell me your opinion about this news...
Regeneron shares rose 2.2% in premarket trading
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading
看
1,089
回复
评论
点赞
8
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-06
Pls like and comment
Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer
(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains
Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer
看
1,590
回复
1
点赞
5
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-04
Pls like 👍
5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023
These were some of the fastest-growing large-cap stocks on the planet over a three-year stretch.
5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023
看
1,917
回复
评论
点赞
7
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-03
Pls like
Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania
Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements
Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania
看
1,690
回复
评论
点赞
1
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-02
Pls like
Cathie Wood Stands to Make a Lot of Money From Skillz Stock
SKLZ stock, while volatile, has the potential to be a 10-bagger
Cathie Wood Stands to Make a Lot of Money From Skillz Stock
看
1,785
回复
评论
点赞
4
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574927270640767","uuid":"3574927270640767","gmtCreate":1611834519815,"gmtModify":1625538661889,"name":"junior_daddy","pinyin":"juniordaddyjuniordaddy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":62,"headSize":417,"tweetSize":215,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.13","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":871032924,"gmtCreate":1636992768969,"gmtModify":1636992769258,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871032924","repostId":"1105194762","repostType":4,"repost":{"id":"1105194762","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636990511,"share":"https://ttm.financial/m/news/1105194762?lang=&edition=full","pubTime":"2021-11-15 23:35","market":"us","language":"en","title":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars","url":"https://stock-news.laohu8.com/highlight/detail?id=1105194762","media":"Tiger Newspress","summary":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.","content":"<p>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-15 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105194762","content_text":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.","news_type":1,"symbols_score_info":{".IXIC":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":1364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847946892,"gmtCreate":1636475732215,"gmtModify":1636475733291,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847946892","repostId":"1127189501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1900,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844264318,"gmtCreate":1636432279510,"gmtModify":1636432280528,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844264318","repostId":"1121670869","repostType":4,"isVote":1,"tweetType":1,"viewCount":1871,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034736,"gmtCreate":1636376382655,"gmtModify":1636376383707,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/844034736","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://ttm.financial/m/news/1141245956?lang=&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1495,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034413,"gmtCreate":1636376371509,"gmtModify":1636376372559,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844034413","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://ttm.financial/m/news/1141245956?lang=&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1300,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034236,"gmtCreate":1636376360851,"gmtModify":1636376361825,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844034236","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://ttm.financial/m/news/1141245956?lang=&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-08 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p>\n<p><img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p>\n<p>The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p>\n<p>Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p>\n<p>The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p>\n<p>During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p>\n<p>The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p>\n<p>It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1089,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842674025,"gmtCreate":1636175962142,"gmtModify":1636175963148,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like and comment ","listText":"Pls like and comment ","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842674025","repostId":"1173813098","repostType":4,"repost":{"id":"1173813098","kind":"news","pubTimestamp":1636156499,"share":"https://ttm.financial/m/news/1173813098?lang=&edition=full","pubTime":"2021-11-06 07:54","market":"us","language":"en","title":"Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer","url":"https://stock-news.laohu8.com/highlight/detail?id=1173813098","media":"Reuters","summary":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains ","content":"<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.</p>\n<p>The S&P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.</p>\n<p>The Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.</p>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.</p>\n<p>The news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.</p>\n<p>\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.</p>\n<p>The Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.</p>\n<p>For the week, the S&P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.</p>\n<p>Travel stocks rose following Pfizer's announcement, with the S&P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.</p>\n<p>\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.</p>\n<p>Among S&P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.</p>\n<p>Healthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.</p>\n<p>Shares of so-called \"stay-at-home\" names fell, with <a href=\"https://laohu8.com/S/ZM\">Zoom</a> Video Communications down 6.2% and Netflix Inc off 3.4%.</p>\n<p>Better-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.</p>\n<p>Pinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.</p>\n<p>Peloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.</p>\n<p>The S&P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.</p>\n<p>About 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall St books records, weekly gains on strong jobs report, Pfizer COVID-19 pill cheer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-06 07:54 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=19167545><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19167545\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞",".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19167545","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173813098","content_text":"(Reuters) - Wall Street's main indexes scored record closing highs on Friday and booked solid gains for the week following a strong U.S. jobs report and positive data for Pfizer's experimental pill against COVID-19.\nThe S&P 500 and the Nasdaq notched record high closes for their seventh straight sessions, while the Dow Jones Industrial Average also closed at a record. All three indexes posted weekly gains for their fifth straight weeks.\nThe Labor Department report showed U.S. employment increased more than expected in October as the headwind from the surge in COVID-19 infections over the summer subsided.\nA trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease. Pfizer shares jumped about 11%.\nThe news kept the run going for equities after investors earlier in the week digested the Federal Reserve's decision to start reducing its monthly bond purchases put in place to support the economy.\n\"Momentum that we have seen this week has continued, and the jobs report and the Pfizer announcement certainly are providing positive datapoints for investors to put more money into the market right now,” said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana.\nThe Dow Jones Industrial Average rose 203.72 points, or 0.56%, to 36,327.95, the S&P 500 gained 17.47 points, or 0.37%, to 4,697.53 and the Nasdaq Composite added 31.28 points, or 0.2%, to 15,971.59.\nFor the week, the S&P 500 rose 2%, the Dow added 1.42%, while the Nasdaq gained 3.05%.\nTravel stocks rose following Pfizer's announcement, with the S&P 1500 airlines index climbing 7%, and cruise operators Carnival Corp, Royal Caribbean Cruises and Norwegian Cruise rising between about 8% to 9%.\n\"Still early to be definitive but this (pill) looks like a true game changer for many industries like leisure and transportation, you're seeing it reflected in the prices,\" said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.\nAmong S&P 500 sectors, energy and industrials led the way, rising 1.4% and 1%, respectively.\nHealthcare was the only sector that ended negative, falling 1%. The Pfizer news weighed on shares of competitors such as Merck, which fell nearly 10%, and COVID-19 vaccine makers such as Moderna, which slumped 16.6%.\nShares of so-called \"stay-at-home\" names fell, with Zoom Video Communications down 6.2% and Netflix Inc off 3.4%.\nBetter-than-expected third-quarter earnings have helped lift sentiment for equities. With about 440 companies having reported, S&P 500 earnings are expected to have climbed 41.5% in the third quarter from a year earlier, according to Refinitiv IBES.\nPinterest Inc shares climbed 5.9% after the company's strong fourth-quarter revenue forecast.\nPeloton Interactive Inc shares slumped 35.3% after the company slashed its full-year sales forecast by up to $1 billion.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.16-to-1 ratio; on Nasdaq, a 1.22-to-1 ratio favored advancers.\nThe S&P 500 posted 83 new 52-week highs and two new lows; the Nasdaq Composite recorded 303 new highs and 80 new lows.\nAbout 11.5 billion shares changed hands in U.S. exchanges, compared with the 10.5 billion daily average over the last 20 sessions.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846055534,"gmtCreate":1636036536957,"gmtModify":1636036936332,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like 👍 ","listText":"Pls like 👍 ","text":"Pls like 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846055534","repostId":"1144131531","repostType":4,"repost":{"id":"1144131531","kind":"news","pubTimestamp":1636022596,"share":"https://ttm.financial/m/news/1144131531?lang=&edition=full","pubTime":"2021-11-04 18:43","market":"us","language":"en","title":"5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=1144131531","media":"Motley Fool","summary":"These were some of the fastest-growing large-cap stocks on the planet over a three-year stretch.","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Be careful: Sales growth alone doesn't always give you the full story about a company.</li>\n</ul>\n<p>Since the Great Recession ended in 2009, no group of companies has performed better than growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.</p>\n<p>And it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddae655c5dfcf584e1db5b561b7b2051\" tg-width=\"2000\" tg-height=\"1529\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Nio: 447% implied sales growth by 2023</b></p>\n<p>Electric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and <b>Nio</b>(NYSE:NIO) is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.</p>\n<p>It's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.</p>\n<p>Nio's rapid sales growth is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.</p>\n<p>In exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.</p>\n<p>Assuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6a0952a9abfc3d69f1c7af0861a2d97b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Snowflake: 401% implied sales growth by 2023</b></p>\n<p>Although double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company <b>Snowflake</b>(NYSE:SNOW) seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.</p>\n<p>The Snowflake growth story is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.</p>\n<p>Further, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.</p>\n<p>The big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537b181fc66378021049916184ef4425\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Sea Limited: 322% implied sales growth by 2023</b></p>\n<p>Another large-cap stock with big-time sales-growth expectations is Singapore-based <b>Sea Limited</b>(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.</p>\n<p>Sea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate is significantly higher than the industry average.</p>\n<p>The company's most exciting segment is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.</p>\n<p>Lastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2d05a27ae059e7e27dd31e695de449b2\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>AMC Entertainment: 313% implied sales growth by 2023</b></p>\n<p>Sometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock <b>AMC Entertainment</b>(NYSE:AMC) is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.</p>\n<p>Whether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.</p>\n<p>Even though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.</p>\n<p>As for the company, it's unlikely to be profitable any time before 2024, and the math simply doesn't check out as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.</p>\n<p>Even with \"rapid sales growth,\" some companies should be avoided like the plague.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b5fc13611f3bbe728494e0ef9d530643\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p><b>Moderna: 1,304% implied sales growth by 2023</b></p>\n<p>The kingpin of sales growth on this list among large-cap companies is biotech-stock <b>Moderna</b>(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.</p>\n<p>Chances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.</p>\n<p>The big unknown for Moderna is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.</p>\n<p>On the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.</p>\n<p>Considering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-04 18:43 GMT+8 <a href=https://www.fool.com/investing/2021/11/04/5-large-cap-stocks-increase-sales-313-to-1304/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nBe careful: Sales growth alone doesn't always give you the full story about a company.\n\nSince the Great Recession ended in 2009, no group of companies has performed better than growth ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/04/5-large-cap-stocks-increase-sales-313-to-1304/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd","SNOW":"Snowflake","AMC":"AMC院线","NIO":"蔚来","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/11/04/5-large-cap-stocks-increase-sales-313-to-1304/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144131531","content_text":"Key Points\n\nBe careful: Sales growth alone doesn't always give you the full story about a company.\n\nSince the Great Recession ended in 2009, no group of companies has performed better than growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.\nAnd it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.\nIMAGE SOURCE: GETTY IMAGES.\nNio: 447% implied sales growth by 2023\nElectric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and Nio(NYSE:NIO) is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.\nIt's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.\nNio's rapid sales growth is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.\nIn exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.\nAssuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 401% implied sales growth by 2023\nAlthough double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company Snowflake(NYSE:SNOW) seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.\nThe Snowflake growth story is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.\nFurther, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.\nThe big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.\nIMAGE SOURCE: GETTY IMAGES.\nSea Limited: 322% implied sales growth by 2023\nAnother large-cap stock with big-time sales-growth expectations is Singapore-based Sea Limited(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.\nSea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate is significantly higher than the industry average.\nThe company's most exciting segment is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.\nLastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.\nIMAGE SOURCE: GETTY IMAGES.\nAMC Entertainment: 313% implied sales growth by 2023\nSometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock AMC Entertainment(NYSE:AMC) is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.\nWhether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.\nEven though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.\nAs for the company, it's unlikely to be profitable any time before 2024, and the math simply doesn't check out as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.\nEven with \"rapid sales growth,\" some companies should be avoided like the plague.\nIMAGE SOURCE: GETTY IMAGES.\nModerna: 1,304% implied sales growth by 2023\nThe kingpin of sales growth on this list among large-cap companies is biotech-stock Moderna(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.\nChances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.\nThe big unknown for Moderna is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.\nOn the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.\nConsidering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.","news_type":1,"symbols_score_info":{"AMC":0.9,"MRNA":0.9,"NIO":0.9,"SE":0.9,"SNOW":0.9}},"isVote":1,"tweetType":1,"viewCount":1917,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848062168,"gmtCreate":1635948641869,"gmtModify":1635948740884,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848062168","repostId":"1100947774","repostType":2,"repost":{"id":"1100947774","kind":"news","pubTimestamp":1635943689,"share":"https://ttm.financial/m/news/1100947774?lang=&edition=full","pubTime":"2021-11-03 20:48","market":"us","language":"en","title":"Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania","url":"https://stock-news.laohu8.com/highlight/detail?id=1100947774","media":"Bloomberg","summary":"Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements ","content":"<p>Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements has fueled a rally in other retail-trader favorites, causing chatrooms like StockTwits to light up with optimistic comments.</p>\n<p>The retailer soared 55% in trading before Wednesday’s U.S. stock-market open, the day after releasing plans to help its turnaround. The advance triggered gains in original meme stocks like AMC Entertainment Holdings Inc.,GameStop Corp., and Koss Corp. in early trading.</p>\n<p>Retailer Bed Bath & Beyond was among the many so-called meme stocks that saw meteoric gains turn to pain earlier this year amid concern about the company’s fundamentals. Shares closed at their lowest level in more than a year last week amid muted expectations afterquarterly sales missedestimates.</p>\n<p><img src=\"https://static.tigerbbs.com/7f583ea80b3b20cd507d78e8311965aa\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"></p>\n<p>This week’s resurgence is likely fueled in part by FOMO -- fear of missing out -- and those who have bought into the investing mantra of YOLO -- you only live once. The appetite for risky investments among retail traders appears to be rising, according to Vanda Research.</p>\n<p>The red-hot rally comes just a day after Avis Budget Group Inc. more than doubled amid a flurry of retail-crazed trading. While investors cheered the surges, Wall Street analysts voiced warnings that the gains ignore reality.</p>\n<p>Loop Capital Markets’ Anthony Chukumba downgraded Bed Bath & Beyond to sell, saying the purveyor of home goods has “lost market share, mind share, and consumer relevance” with none of the updates materially changing his skeptical view on the stock. Avis, which fell about 10% in early trading,was downgraded by both JPMorgan Chase & Co. and Deutsche Bank AG, who warned the company’s $20 billion valuation wasn’t realistic.</p>\n<p>To be fair, Wall Street has warned that valuations for cult-favorites like AMC Entertainment and GameStop have been divorced from reality for more than nine months. But that hasn’t stopped retail traders and hedge funds looking to strike it rich quick.</p>\n<p>For investors who got in before the start of 2021, it’s been lucrative. Movie-theater company AMC Entertainment is up 1,730% and GameStop is up roughly 1,000%, while newer meme stocks like the Donald Trump-tied SPAC, Digital World Acquisition Corp., and Ocugen Inc. have returned more than 500% apiece.</p>\n<p>A basket of 37 retail-trader favorites tracked by Bloomberg News has climbed 5.8% this week, besting a 0.6% return for the S&P 500 Index. The group of stocks preferred by day traders rallied 4.9% on Monday for the best day since late August.</p>\n<p>Here are some retail-favorites that are seeing notable gains before Wednesday’s market open</p>\n<ul>\n <li>AMC Entertainment climbs 5%</li>\n <li>GameStop rises 3.8%</li>\n <li>Koss Corp. rises about 4%</li>\n <li>Naked Brand jumps 3.3%</li>\n</ul>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBed Bath & Beyond’s Stock Surge Revives Retail-Trader Mania\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-03 20:48 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-11-03/bed-bath-beyond-s-stock-surge-revives-retail-trader-mania?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements has fueled a rally in other retail-trader favorites, causing chatrooms like StockTwits to light up ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-11-03/bed-bath-beyond-s-stock-surge-revives-retail-trader-mania?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KOSS":"高斯电子","AMC":"AMC院线","GME":"游戏驿站","BBBY":"3B家居","CAR":"安飞士","OCGN":"Ocugen"},"source_url":"https://www.bloomberg.com/news/articles/2021-11-03/bed-bath-beyond-s-stock-surge-revives-retail-trader-mania?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100947774","content_text":"Excitement that’s triggered a surge in Bed Bath & Beyond Inc. shares after a whirl of announcements has fueled a rally in other retail-trader favorites, causing chatrooms like StockTwits to light up with optimistic comments.\nThe retailer soared 55% in trading before Wednesday’s U.S. stock-market open, the day after releasing plans to help its turnaround. The advance triggered gains in original meme stocks like AMC Entertainment Holdings Inc.,GameStop Corp., and Koss Corp. in early trading.\nRetailer Bed Bath & Beyond was among the many so-called meme stocks that saw meteoric gains turn to pain earlier this year amid concern about the company’s fundamentals. Shares closed at their lowest level in more than a year last week amid muted expectations afterquarterly sales missedestimates.\n\nThis week’s resurgence is likely fueled in part by FOMO -- fear of missing out -- and those who have bought into the investing mantra of YOLO -- you only live once. The appetite for risky investments among retail traders appears to be rising, according to Vanda Research.\nThe red-hot rally comes just a day after Avis Budget Group Inc. more than doubled amid a flurry of retail-crazed trading. While investors cheered the surges, Wall Street analysts voiced warnings that the gains ignore reality.\nLoop Capital Markets’ Anthony Chukumba downgraded Bed Bath & Beyond to sell, saying the purveyor of home goods has “lost market share, mind share, and consumer relevance” with none of the updates materially changing his skeptical view on the stock. Avis, which fell about 10% in early trading,was downgraded by both JPMorgan Chase & Co. and Deutsche Bank AG, who warned the company’s $20 billion valuation wasn’t realistic.\nTo be fair, Wall Street has warned that valuations for cult-favorites like AMC Entertainment and GameStop have been divorced from reality for more than nine months. But that hasn’t stopped retail traders and hedge funds looking to strike it rich quick.\nFor investors who got in before the start of 2021, it’s been lucrative. Movie-theater company AMC Entertainment is up 1,730% and GameStop is up roughly 1,000%, while newer meme stocks like the Donald Trump-tied SPAC, Digital World Acquisition Corp., and Ocugen Inc. have returned more than 500% apiece.\nA basket of 37 retail-trader favorites tracked by Bloomberg News has climbed 5.8% this week, besting a 0.6% return for the S&P 500 Index. The group of stocks preferred by day traders rallied 4.9% on Monday for the best day since late August.\nHere are some retail-favorites that are seeing notable gains before Wednesday’s market open\n\nAMC Entertainment climbs 5%\nGameStop rises 3.8%\nKoss Corp. rises about 4%\nNaked Brand jumps 3.3%","news_type":1,"symbols_score_info":{"AMC":0.9,"BBBY":0.9,"CAR":0.9,"DWAC":0.9,"GME":0.9,"KOSS":0.9,"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1690,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843537042,"gmtCreate":1635840741218,"gmtModify":1635840741544,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574927270640767","authorIdStr":"3574927270640767"},"themes":[],"htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843537042","repostId":"1129449747","repostType":4,"repost":{"id":"1129449747","kind":"news","pubTimestamp":1635839802,"share":"https://ttm.financial/m/news/1129449747?lang=&edition=full","pubTime":"2021-11-02 15:56","market":"us","language":"en","title":"Cathie Wood Stands to Make a Lot of Money From Skillz Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1129449747","media":"InvestorPlace","summary":"SKLZ stock, while volatile, has the potential to be a 10-bagger","content":"<p>The <b>Ark Innovation ETF</b>(NYSEARCA:<b><u>ARKK</u></b>) bought2.1 million shares of <b>Skillz</b>(NYSE:<b><u>SKLZ</u></b>) on Oct. 21., according to <i>24/7 Wall St., t</i>he SKLZ stock buy brings the ETF’s total holdings of the esports gaming platform company to 13.3 million shares.</p>\n<p>Although the SKILLZ position is only good for 0.70% of the ETF’s $19.4 billion in total assets, it’s got a shot at becoming one of the star portfolio manager’s biggest successes.</p>\n<p>Well, maybe not <b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) big, but significant all the same. For example, if Skillz stock miraculously reverted to its all-time high of $46.30, which it hit in February, the ETF’s Skillz shares would be worth $617.2 million and a weighting of 3.18%. That’s good for 11th position. Currently, it’s 34th.</p>\n<p>Since the share purchase, SKLZ stock has gained almost 17% through the second-last trading day in October. It’s on a roll.</p>\n<p><b>SKLZ Stock: Where to From Here?</b></p>\n<p>There is no doubt the short-sellers are battling it out with the Reddit crowd over the ultimate direction of Skillz stock. More than 555 million shares,or 23% of its total, are sold short.</p>\n<p>A short squeeze seems possible in the near term, but the reality, like many stocks, is that neither side appears ready to take the bull by the horns.</p>\n<p>In the interim, Wood keeps building her position in the company.</p>\n<p>Over at the <b>ARK Next Generation Internet ETF</b>(NYSEARCA:<b><u>ARKW</u></b>), the fund holds 7.0 million shares of Skillz, good for 22nd position in ARKW. So, put those two positions together, move up to $46.30 in the blink of an eye, and Ark Investment Management is sitting on a $1 billion investment.</p>\n<p>And it could get even better than that.</p>\n<p>The portfolio manager has been selling little bits of Tesla as it’s moved over $1,000 in recent weeks. On Oct. 21 and 22, she sold more than 126,000 shares for proceeds of $114 million. Then on Oct. 25, she sold another 22,598 shares of Tesla.</p>\n<p>Those proceeds have to go into other stocks at some point.</p>\n<p><b>Another Successful Quarter of Sales Growth</b></p>\n<p>Skillz has been able to string together 22 consecutive quarters of sales growth — profits, or should I say losses, are another story altogether — and looks likely to ring in a 23rd consecutive quarter of strong sales growth when it reports earnings in early November.</p>\n<p>The analyst estimate for Q3 2021 is $102.3 million. The company’s full-year guidance is for $375 million. That doesn’t even include its acquisition of Aarki.</p>\n<p>In July, I suggested that Aarki insiders should hang on to the four million shares of SKLZ stock they got as part of the sale to Skillz.</p>\n<p>“Between Wood’s ownership, the fact that Skillz came public through a Jeff Sagansky and Harry Sloan SPAC, and the company participates in mobile gaming, one of the hottest industries around, I think the risk-reward proposition is excellent between $15 and $20,” I wrote on July 14.</p>\n<p>“If you buy at current prices, be prepared for a lot of volatility. I would not be surprised if it tests $15 on the downside again soon. If you do buy now, I’d keep some cash on the sidelines so you can buy some more at $15 or less.”</p>\n<p>I also said that adding Aarki to the mix should help Skillz keep generating more revenue from users, commonly referred to as ARPU, or average revenue per user.</p>\n<p>In the second quarter, it reported an ARPU of $12.46. That was 20.4% higher than the first quarter of 2021. So if it can keep moving the needle higher, you can be sure the profits will start to roll.</p>\n<p><i>InvestorPlace’s</i> Alex Sirois believes that investors should wait to buy until after the third-quarter results are released before making a move.</p>\n<p>“Losses nearly quadrupled in Q2 on a year-over-year basis, rising to $79.6 million from $20.2 million a year ago. It was a similar story in the first quarter, with the company’s net loss widening to $53.6 million from $15.5 million in the first quarter of 2021,” Sirois stated on Oct. 28.</p>\n<p>“So, although analysts are predicting strong revenue growth, I wouldn’t jump into SKLZ stock until the company proves it can control its losses.”</p>\n<p>While I get where my colleague is coming from, the company has plenty of cash ($692.8 million) to get it through the rest of this fiscal year and all of fiscal 2022. So I would be squarely fixed on top-line growth and ARPU.</p>\n<p>If these two numbers grew sequentially and year-over-year by double digits, all’s good with the company. Worrying about losses at this point is how investors miss out and quality growth stories like Skillz.</p>\n<p>And, besides, as my colleague says, there’s a lot of good things happening in its product development at the moment. So avoid the noise and focus on what matters for SKLZ stock in the near term.</p>\n<p>While Cathie Wood has been both a buyer and seller of SKLZ stock, ultimately, I believe she’ll make out like a bandit.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Stands to Make a Lot of Money From Skillz Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Stands to Make a Lot of Money From Skillz Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-02 15:56 GMT+8 <a href=https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Ark Innovation ETF(NYSEARCA:ARKK) bought2.1 million shares of Skillz(NYSE:SKLZ) on Oct. 21., according to 24/7 Wall St., the SKLZ stock buy brings the ETF’s total holdings of the esports gaming ...</p>\n\n<a href=\"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SKLZ":"Skillz Inc"},"source_url":"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129449747","content_text":"The Ark Innovation ETF(NYSEARCA:ARKK) bought2.1 million shares of Skillz(NYSE:SKLZ) on Oct. 21., according to 24/7 Wall St., the SKLZ stock buy brings the ETF’s total holdings of the esports gaming platform company to 13.3 million shares.\nAlthough the SKILLZ position is only good for 0.70% of the ETF’s $19.4 billion in total assets, it’s got a shot at becoming one of the star portfolio manager’s biggest successes.\nWell, maybe not Tesla(NASDAQ:TSLA) big, but significant all the same. For example, if Skillz stock miraculously reverted to its all-time high of $46.30, which it hit in February, the ETF’s Skillz shares would be worth $617.2 million and a weighting of 3.18%. That’s good for 11th position. Currently, it’s 34th.\nSince the share purchase, SKLZ stock has gained almost 17% through the second-last trading day in October. It’s on a roll.\nSKLZ Stock: Where to From Here?\nThere is no doubt the short-sellers are battling it out with the Reddit crowd over the ultimate direction of Skillz stock. More than 555 million shares,or 23% of its total, are sold short.\nA short squeeze seems possible in the near term, but the reality, like many stocks, is that neither side appears ready to take the bull by the horns.\nIn the interim, Wood keeps building her position in the company.\nOver at the ARK Next Generation Internet ETF(NYSEARCA:ARKW), the fund holds 7.0 million shares of Skillz, good for 22nd position in ARKW. So, put those two positions together, move up to $46.30 in the blink of an eye, and Ark Investment Management is sitting on a $1 billion investment.\nAnd it could get even better than that.\nThe portfolio manager has been selling little bits of Tesla as it’s moved over $1,000 in recent weeks. On Oct. 21 and 22, she sold more than 126,000 shares for proceeds of $114 million. Then on Oct. 25, she sold another 22,598 shares of Tesla.\nThose proceeds have to go into other stocks at some point.\nAnother Successful Quarter of Sales Growth\nSkillz has been able to string together 22 consecutive quarters of sales growth — profits, or should I say losses, are another story altogether — and looks likely to ring in a 23rd consecutive quarter of strong sales growth when it reports earnings in early November.\nThe analyst estimate for Q3 2021 is $102.3 million. The company’s full-year guidance is for $375 million. That doesn’t even include its acquisition of Aarki.\nIn July, I suggested that Aarki insiders should hang on to the four million shares of SKLZ stock they got as part of the sale to Skillz.\n“Between Wood’s ownership, the fact that Skillz came public through a Jeff Sagansky and Harry Sloan SPAC, and the company participates in mobile gaming, one of the hottest industries around, I think the risk-reward proposition is excellent between $15 and $20,” I wrote on July 14.\n“If you buy at current prices, be prepared for a lot of volatility. I would not be surprised if it tests $15 on the downside again soon. If you do buy now, I’d keep some cash on the sidelines so you can buy some more at $15 or less.”\nI also said that adding Aarki to the mix should help Skillz keep generating more revenue from users, commonly referred to as ARPU, or average revenue per user.\nIn the second quarter, it reported an ARPU of $12.46. That was 20.4% higher than the first quarter of 2021. So if it can keep moving the needle higher, you can be sure the profits will start to roll.\nInvestorPlace’s Alex Sirois believes that investors should wait to buy until after the third-quarter results are released before making a move.\n“Losses nearly quadrupled in Q2 on a year-over-year basis, rising to $79.6 million from $20.2 million a year ago. It was a similar story in the first quarter, with the company’s net loss widening to $53.6 million from $15.5 million in the first quarter of 2021,” Sirois stated on Oct. 28.\n“So, although analysts are predicting strong revenue growth, I wouldn’t jump into SKLZ stock until the company proves it can control its losses.”\nWhile I get where my colleague is coming from, the company has plenty of cash ($692.8 million) to get it through the rest of this fiscal year and all of fiscal 2022. So I would be squarely fixed on top-line growth and ARPU.\nIf these two numbers grew sequentially and year-over-year by double digits, all’s good with the company. Worrying about losses at this point is how investors miss out and quality growth stories like Skillz.\nAnd, besides, as my colleague says, there’s a lot of good things happening in its product development at the moment. So avoid the noise and focus on what matters for SKLZ stock in the near term.\nWhile Cathie Wood has been both a buyer and seller of SKLZ stock, ultimately, I believe she’ll make out like a bandit.","news_type":1,"symbols_score_info":{"SKLZ":0.9}},"isVote":1,"tweetType":1,"viewCount":1785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}